Literature DB >> 8783349

Effectiveness of a whole cell pertussis vaccine in child-care centers and schools.

G De Serres1, N Boulianne, B Duval, P Déry, A M Rodriguez, R Massé, S Halperin.   

Abstract

BACKGROUND: Pertussis has substantially increased in Quebec, Canada, since 1990. We estimated pertussis vaccine effectiveness and vaccine coverage in child-care centers and elementary schools.
METHODS: Two retrospective cohort studies were simultaneously conducted. One included 4482 children attending 88 public child-care centers and the other included 3429 pupils in 14 elementary schools. Cough and pertussis symptoms were assessed through a questionnaire and medical records; immunization status was ascertained by examination of written records.
RESULTS: In child-care centers 95% of children had received at least three vaccine doses at the beginning of the follow-up; in schools more than 98% of pupils had received at least 4 doses. With > or = 4 doses of vaccine and a standard case definition used for surveillance (cough > or = 2 weeks, > or = 1 pertussis symptom and no other apparent cause for cough), vaccine effectiveness was estimated at 61% (95% confidence interval, 44 to 72%) in child-care centers and at 60% (95% confidence interval, 10 to 82%) in schools. With the same number of doses but a case definition requiring a cough > or = 5 weeks, vaccine effectiveness increased to 71% (95% confidence interval, 49 to 83) in child-care centers and to 86% (95% confidence interval, 66 to 94%) in schools.
CONCLUSIONS: The increase in pertussis in Quebec is not caused by a low vaccine coverage. A low vaccine effectiveness may contribute to the resurgence of pertussis in the past decade.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783349     DOI: 10.1097/00006454-199606000-00009

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Economic evaluation of a new acellular vaccine for pertussis in Canada.

Authors:  M Iskedjian; T R Einarson; B J O'Brien; J G De Serres; R Gold; I M Gemmill; N Milkovich; A Rosner
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Has the change to acellular pertussis vaccine improved or worsened pertussis control?

Authors:  Scott A Halperin; Gaston De Serres
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

4.  The role of the acellular pertussis vaccine and the demise of 'Pertussis Pete'.

Authors:  J M Conly; B L Johnston
Journal:  Can J Infect Dis       Date:  2001-01

Review 5.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

6.  The return of the 100-day cough: resurgence of pertussis in the 1990s.

Authors:  T W Tam; A Bentsi-Enchill
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 7.  Licensed pertussis vaccines in the United States. History and current state.

Authors:  Nicola P Klein
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

8.  Effectiveness of pertussis vaccination and duration of immunity.

Authors:  Kevin L Schwartz; Jeffrey C Kwong; Shelley L Deeks; Michael A Campitelli; Frances B Jamieson; Alex Marchand-Austin; Therese A Stukel; Laura Rosella; Nick Daneman; Shelly Bolotin; Steven J Drews; Heather Rilkoff; Natasha S Crowcroft
Journal:  CMAJ       Date:  2016-09-26       Impact factor: 8.262

Review 9.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Pertussis Surveillance Trends in British Columbia, Canada, over a 20-year Period: 1993-2013.

Authors:  C Chambers; D M Skowronski; L Hoang; H Guiyun Li; C E Fritz; R Gustafson; M Murti; A Reid; R Parker; D Bowering
Journal:  Can Commun Dis Rep       Date:  2014-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.